Skip to main content

Faasos parent Rebel Foods to run 150 Wendy’s restaurants; India on course to becoming 5G leader

Homegrown cloud-kitchen operator Rebel Foods has acquired the master franchise rights for global fast food chain Wendy's in India to scale up the latter's restaurant stores in the country.
Daily Top 5

A closer look at today's biggest tech and startup stories and why they matter

Good evening Reader,

Homegrown cloud-kitchen operator Rebel Foods has acquired the master franchise rights for global fast food chain Wendy's in India to scale up the latter's restaurant stores in the country.

We have this and more in today's ETtech Top 5

Also in this letter:
■ Musk looking for researchers to rival OpenAI
■ Infographic Insight: Google leads the pack in ad revenue
■ Cashfree acquires one-click checkout platform Zecpe
Faasos parent Rebel Foods to run US fast-food chain Wendy's in India

Rebel Foods Wendy

Wendy's has struck a deal with Rebel Foods to scale the fast food chain's physical presence in India to 150 locations.

Deal Details: In the expanded relationship, Rebel Foods will develop about 150 traditional Wendy's restaurants over the next decade. Wendy's is in 90 locations across 19 cities at present, with its three traditional restaurants being operated by Rebel.

Quote unquote: "India is a strategic, high-growth potential market for us," Abigail Pringle, president, international and chief development officer, The Wendy's Company, said.

She added that Rebel Foods is expanding its franchise commitment to accelerate Wendy's footprint across the country with a mix of traditional outlets and cloud kitchens.

Catch up-quick: This deal takes forward their earlier partnership signed in 2020, under which Rebel Foods will launch 250 former's delivery-only stores, also known as cloud kitchens, in India.

The cloud kitchen, which houses brands like Behrouz Biryani, Oven Story, and Faasos, had also cut its workforce earlier this year.
Liked reading? Share this story
whatuphate ithate it

India in talks with 18 countries for 4G/5G implementation: Ashwini Vaishnaw

Ashwini Vaishnaw

The communication and information technology minister Ashwini Vaishnaw said on Tuesday that India is in talks with 18 countries that are keen to implement the 4G/5G technology stack. He further added that the whole country will get 5G coverage by 2024 and India has already got 100 patents for 6G telecom technology.

Quote Unquote: "These are some of the best (countries) in the world (that are looking to adopt the stack)," Vaishnaw told reporters. "This is a 4G/5G stack that is upgradeable. What we have installed, those same devices will be doing 5G also. Technology has to be tested, and ruggedised, then only we will move to the next. That's why we are doing 4G first (with Bharat Sanchar Nigam Limited) and then 5G."

Telecom reforms: Vaishnaw said India's telecom sector was plagued with numerous problems such as litigation and legacy issues, but has now emerged as a 'sunrise sector' that is investment-oriented and employment-generating.

"Our next major target is getting the Telecom Bill passed in the coming Monsoon session (of Parliament). That will lead to a major series of reforms, in terms of spectrum, licences and regulation. There will be significant reform because of the Bill."

Manufacturing progress: While speaking about the progress on the manufacturing front, Vaishnaw said the first eNodeB, which was designed and made in India, was installed in Chandigarh.

A base station for a cellular network usually consists of a tower and equipment hut. Evolved NodeB or eNodeB is the base station equipment that handles the radio interface with smartphones
Liked reading? Share this story
whatuphate ithate it

Subscribe to our daily newsletter ETtech Morning Dispatch for the latest insights from the world of technology and startups.

Subscribe
Elon Musk hiring AI researchers to develop OpenAI rival: report

Elon Musk

Tech billionaire Elon Musk has approached several artificial intelligence (AI) researchers in recent weeks to form a new lab that will work on developing an alternative to ChatGPT, according to US tech publication The Information.

Alphabet's ex-employee: Among the researchers Musk has approached, one prominent name is that of Igor Babuschkin, a former member of Alphabet's DeepMind AI unit. Babuschkin specialises in the kind of machine-learning models that power chatbots like ChatGPT.

Though Babuschkin has not officially agreed to work with Musk, he said, he'd like to work with him on something in the LLM (large language model) space.

Rivalling OpenAI: Musk co-founded OpenAI in 2015 along with a small group of entrepreneurs and AI researchers, including Sam Altman, former president of Y Combinator, and Ilya Sutskever, a former Google expert on machine learning.

He served on OpenAI's board until 2018 but left to focus on Tesla. Over the last few months, Musk has repeatedly criticised the company for installing safeguards that prevent ChatGPT from producing text that might offend users.

Also read | Twitter employees to receive "very significant" performance-based stock awards: Elon Musk

Tweet of the day

Liked reading? Share this story
whatuphate ithate it

Infographic Insight: Google rules search ad space

Google

Google enjoyed the lion's share of 58% in search advertising revenue last year, while China's Baidu was a distant second at 15%.

Amazon remained at third spot with 14% share in ad revenue in 2022. Microsoft's Bing was far behind with just 6% share.

Google has dominated search and the search ad market for almost 25 years.

Google leading the pack

Meanwhile, Microsoft recently announced it will integrate OpenAI's chatbot ChatGPT with Bing to take on Google.

"It's a new day in search. It's a new paradigm for search," Microsoft CEO Satya Nadella said.

In 2022, Microsoft saw $18 billion in ad revenue through search and LinkedIn. Google, meanwhile, pulled in $59 billion in Q4 alone, according to a Business Insider report.
Liked reading? Share this story
whatuphate ithate it

Cashfree Payments acquires one-click checkout platform Zecpe

Cashfree Payments acquires Zecpe

Akash Sinha, cofounder and CEO, Cashfree Payments

Cashfree Payments has announced that it has acquired one-click checkout company Zecpe.

This is the payment firm's second acquisition. Cashfree had picked up a majority stake in UAE-based payment solution provider Telr in 2021 for $15 million, to expand into the Middle Eastern markets and bolster its cross-border payment capabilities.

As a part of the transaction, Zecpe founder Hriday Agarwal along with his team will be joining Cashfree Payments.

"We are certain that this acquisition will strengthen our D2C one-click checkout capabilities and further elevate our leadership position in the SMB space," said Akash Sinha, chief executive, and cofounder, Cashfree Payments.

RBI diktat: The acquisition comes at a time when Cashfree has been banned from onboarding new users for payment gateway services by the Reserve Bank of India (RBI). Amid the ongoing funding crunch, Cashfree laid off close to 100 employees in January, this year, to reduce its burn.

Today's ETtech Top 5 newsletter was curated by Megha Mishra in Mumbai and Gaurab Dasgupta in New Delhi. Graphics and illustrations by Rahul Awasthi.

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
Thanks for reading. We'll be back tomorrow with more interesting stories and updates. Follow us on Twitter and Facebook.

How do you like today's newsletter?

hate it hate it meh meh love it love it

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side